A Phase 3b, Multi-Center, Randomized-withdrawal, Placebo-Controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45-120mg/day, Split-dose) in Subjects with Chronic Kidney Disease Stage 4 due to Autosomal Dominant Polycystic Kidney Disease.
Along with his co-authors — including former trainees in
the Department of Orthopaedics — Leslie J.
Bisson, MD, has won an award from the Orthopaedic Journal of
Sports Medicine for authoring the “most outstanding
clinical paper” to appear in the publication in 2016.
To meet Western New York’s growing need for quality care
for Alzheimer’s disease and related disorders, the
Alzheimer’s Disease and Memory Disorders Center has expanded
its clinics in Buffalo and Williamsville.